LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL - Part 2 - Bevacizumab analysis -
nSMOL is Shimadzu's completely new and breakthrough technology that enables selective proteolysis of the Fab region of monoclonal antibodies. This technique facilitates method development independent of a variety of antibody drugs and achieves a paradigm shift in the bioanalysis of antibody drugs.
Furthermore, this is the only method with respect to antibody drugs that has fulfilled the criteria of "Guideline on Bioanalytical Method Validation in Pharmaceutical Development" for low MW drug compounds issued by the Japanese Ministry of Health, Labour and Welfare. Shimadzu also offers optimization methods and protocols, and nSMOL can be applied to clinical research at various institutions.
- Content Type:
- Application
- Document Number:
- LAAN-A-LM-E117A
- Product Type:
- Liquid Chromatograph-Mass Spectrometry, Mass Spectrometry
- Keywords:
- nSMOL, LCMS Bioanalysis, Antibody drug, Fab-selective proteolysis, Bevacizumab, Pharmaceutical, Life Science, LCMS-8050, LCMS-8060, NexeraX2 System
- Language:
- English
- File Name:
- jpo117016.pdf
- File Size:
- 621kb